Imatinib: the first 3 years (Q35045480)

6 August 2017

1 reference

title

Imatinib: the first 3 years (English)

1 reference

6 August 2017

1 reference

Renaud Capdeville

1

1 reference

PubMed ID

12528777

6 August 2017

Sandra Silberman

series ordinal

2

1 reference

PubMed ID

12528777

6 August 2017

Sasa Dimitrijevic

series ordinal

3

1 reference

6 August 2017

1 September 2002

1 reference

European Journal of Cancer

6 August 2017

1 reference

6 August 2017

38 Suppl 5

1 reference

6 August 2017

S77-82

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980607-4

7 January 2021

10.1016/S0959-8049(02)80607-4

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f7nudo2tuzdbvk2vbl6jqhgxni

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_f7nudo2tuzdbvk2vbl6jqhgxni

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f7nudo2tuzdbvk2vbl6jqhgxni

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/f7nudo2tuzdbvk2vbl6jqhgxni

30 July 2022